N C Tebbutt

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Australia

Publications

  1. doi request reprint Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
    Niall Tebbutt
    Department of Medical Oncology, Austin Health, Heidelberg, Vic, 3084, Australia
    Cancer Chemother Pharmacol 75:993-1004. 2015
  2. pmc Can we accurately report PTEN status in advanced colorectal cancer?
    Christopher Hocking
    The Queen Elizabeth Hospital, TQEH Woodville Road, Woodville South, SA 5011, Australia
    BMC Cancer 14:128. 2014
  3. pmc Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis
    D Damianovich
    Ludwig Institute for Cancer Research, Austin Health, Melbourne, Victoria, Australia
    Br J Cancer 96:546-50. 2007
  4. pmc The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
    Lee S Rosen
    Department of Medicine, University of California Los Angeles, Santa Monica, CA, USA
    BMC Cancer 13:242. 2013
  5. pmc An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]
    Stephen Clarke
    Royal North Shore Hospital, St Leonards, NSW 2065, Australia
    BMC Cancer 13:120. 2013
  6. pmc Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
    N C Tebbutt
    Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Br J Cancer 108:771-4. 2013
  7. doi request reprint Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
    Andrew J Weickhardt
    Ludwig Institute for Cancer Research, Australia
    J Clin Oncol 30:1505-12. 2012
  8. pmc Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus
    Rachel A Davey
    Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
    Lipids Health Dis 5:29. 2006
  9. pmc Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
    Dusan Kotasek
    Adelaide Cancer Center, Level 1, Tennyson Centre, 520 South Road, Kurralta Park, SA 5037, Australia
    BMC Cancer 11:313. 2011
  10. doi request reprint Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    N C Tebbutt
    Department of Medical Oncology, Austin Health, Melbourne, Australia
    Ann Oncol 22:1834-8. 2011

Collaborators

Detail Information

Publications26

  1. doi request reprint Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
    Niall Tebbutt
    Department of Medical Oncology, Austin Health, Heidelberg, Vic, 3084, Australia
    Cancer Chemother Pharmacol 75:993-1004. 2015
    ....
  2. pmc Can we accurately report PTEN status in advanced colorectal cancer?
    Christopher Hocking
    The Queen Elizabeth Hospital, TQEH Woodville Road, Woodville South, SA 5011, Australia
    BMC Cancer 14:128. 2014
    ..Difficulties in the methodological assessment of PTEN are likely to be a major contributor to recent conflicting results...
  3. pmc Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis
    D Damianovich
    Ludwig Institute for Cancer Research, Austin Health, Melbourne, Victoria, Australia
    Br J Cancer 96:546-50. 2007
    ..Older patients (> or =70 years) had inferior survival no matter which drug was used as initial treatment. Analysis of the Australian HIC database provides a valuable means of assessing patterns of use and outcomes of new therapies...
  4. pmc The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
    Lee S Rosen
    Department of Medicine, University of California Los Angeles, Santa Monica, CA, USA
    BMC Cancer 13:242. 2013
    ..Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit. We assessed effects of motesanib on gallbladder size and function...
  5. pmc An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]
    Stephen Clarke
    Royal North Shore Hospital, St Leonards, NSW 2065, Australia
    BMC Cancer 13:120. 2013
    ....
  6. pmc Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
    N C Tebbutt
    Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Br J Cancer 108:771-4. 2013
    ..Cetuximab can reverse chemotherapy resistance in colorectal cancer. This study evaluated the efficacy and safety of the combination of docetaxel and cetuximab as a second-line treatment in docetaxel-refractory oesophagogastric cancer...
  7. doi request reprint Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
    Andrew J Weickhardt
    Ludwig Institute for Cancer Research, Australia
    J Clin Oncol 30:1505-12. 2012
    ..This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC)...
  8. pmc Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus
    Rachel A Davey
    Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
    Lipids Health Dis 5:29. 2006
    ..Type 2 DM plays a vital role both in allowing expression of severe combined hyperlipoproteinaemia, in addition to serving as a risk factor for complications such as tissue infiltration...
  9. pmc Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
    Dusan Kotasek
    Adelaide Cancer Center, Level 1, Tennyson Centre, 520 South Road, Kurralta Park, SA 5037, Australia
    BMC Cancer 11:313. 2011
    ....
  10. doi request reprint Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    N C Tebbutt
    Department of Medical Oncology, Austin Health, Melbourne, Australia
    Ann Oncol 22:1834-8. 2011
    ..Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab...
  11. doi request reprint Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    Niall C Tebbutt
    Austin Health, Studley Rd, Heidelberg, Victoria, 3084, Australia
    J Clin Oncol 28:3191-8. 2010
    ..To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial...
  12. pmc Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
    N C Tebbutt
    Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Br J Cancer 102:475-81. 2010
    ..Weekly docetaxel is associated with less haematological toxicity. This randomised phase II study tested weekly docetaxel-based combination chemotherapy regimens, with the aim of maintaining their activity while reducing toxicity...
  13. ncbi request reprint Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)
    T J Price
    Queen Elizabeth Hospital, Adelaide, Australia National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia Perth Oncology, Mount Hospital, Perth, Australia Christchurch Hospital, Christchurch, New Zealand Geelong Hospital, Geelong, Australia Frankston Hospital, Frankston, Australia Calvary Mater Hospital, Newcastle, Australia Austin Health, Heidelberg, Australia
    J Clin Oncol 29:510. 2011
    ..510 Background: In an aging population a greater proportion of geriatric patients will be considered for systemic chemotherapy. CRC is a common cancer and will be a major health issue in geriatrics...
  14. ncbi request reprint International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
    T J Price
    Queen Elizabeth Hospital, Adelaide, Australia NHMRC Clinical Trials Centre, Sydney, Australia Sir Charles Gardener, Perth, Australia Christchurch Hospital, Christchurch, New Zealand Barwon Health, Geelong, Australia Frankston Hospital, Melbourne, Australia Royal Marsden Hospital, London, United Kingdom Austin Health, Melbourne, Australia
    J Clin Oncol 26:4029. 2008
    ..Patients with mCRC considered suitable for single agent FU chemotherapy were randomised to Cap, CapBev or to CapBev + MMC (MCapBev). The primary outcome is PFS, with safety an important secondary outcome...
  15. ncbi request reprint Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)
    T J Price
    The Queen Elizabeth Hospital, Woodville, Australia National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia ANZGOG, Camperdown, Australia University of Western Australia, Perth, Australia Christchurch Hospital, Christchurch, New Zealand Geelong Hospital, Geelong, Australia Frankston Hospital, Frankston, Australia Calvary Mater Hospital, Newcastle, Australia Ludwig Oncology Unit, Austin Hospital, Heidelberg, Australia
    J Clin Oncol 29:3621. 2011
    ..3621 Background: With age the frequency of cancer and chronic disease increases. CRC is a common cancer and treatment with chemotherapy and biological agents will be a major health issue in the elderly...
  16. ncbi request reprint ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer-Final results of a multicentre phase II trial by the AGITG
    N C Tebbutt
    Austin Health, Heidelberg, Victoria, Australia NHMRC Clinical Trials Centre, Sydney, Australia Monash Medical Centre, Melbourne, Australia Sir Charles Gairdner Hospital, Perth, Australia Royal North Shore Hospital, Sydney, Australia Frankston Hospital, Melbourne, Australia Austin Health, Melbourne, Australia
    J Clin Oncol 26:15554. 2008
    ..This study evaluated the efficacy and safety of the combination of docetaxel and cetuximab as second-line treatment in docetaxel-refractory OG cancer...
  17. doi request reprint Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
    T J Price
    Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, Australia
    Ann Oncol 23:1531-6. 2012
    ..We used the MAX population to investigate whether age affected the improved outcome found in CRC when bevacizumab is added to capecitabine chemotherapy...
  18. ncbi request reprint Comparing utilities for advanced colorectal cancer valued from societal and cancer patients' perspectives using baseline data from the MAX study
    M R Stockler
    University of Sydney, Sydney, Australia Queen Elizabeth Hospital, Adelaide, Australia Sir Charles Gairdner Hospital, Perth, Australia Christchurch Hospital, Christchurch, New Zealand Barwon Health Geelong Hospital, Geelong, Australia Frankston Hospital, Melbourne, Australia Austin Health, Melbourne, Australia
    J Clin Oncol 26:6504. 2008
    ..The purpose of this study was to compare utilities from 2 instruments based on different valuations, questions and algorithms...
  19. ncbi request reprint International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial
    N C Tebbutt
    Austin Health, Heidelberg, Australia NHMRC Clinical Trials Centre, Sydney, Australia The Canberra Hospital, Canberra, Australia Christchurch Hospital, Christchurch, New Zealand The Geelong Hospital, Geelong, Australia Royal Marsden Hospital, London, United Kingdom Queen Elizabeth Hospital, Adelaide, Australia
    J Clin Oncol 27:4023. 2009
    ..This phase III study compared Cap with Cap Bev and Cap Bev MMC. The aim was to develop a low toxicity regimen suitable for a broad population of pts with mCRC...
  20. ncbi request reprint Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study
    G A van Hazel
    University of Western Australia, Perth, Australia NCIC Clinical Trials Group, Kingston, ON, Canada Ludwig Oncology Unit, Austin Hospital, Heidelberg, Australia The Ottawa Hospital and the University of Ottawa, Ottawa, ON, Canada The Queen Elizabeth Hospital, Woodville, Australia Peter MacCallum Cancer Centre, Melbourne, Australia Cancer Center for Southern Interior, Kelowna, BC, Canada Monash Medical Centre, East Bentleigh, Australia Kingston Regional Cancer Centre, Kingston, ON, Canada The Canberra Hospital, Canberra, Australia ANZGOG, Camperdown, Australia Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK, Canada St George Hospital, Kogarah, Australia St John Regional Hospital, Saint John, NB, Canada Flinders Medical Centre, Adelaide, Australia
    J Clin Oncol 29:3602. 2011
    ..We compared tumour measurement as a continuous variable and visualized by waterfall plot vs. categorized as response based on RECIST as potential early predictors of OS benefit...
  21. ncbi request reprint The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17
    M M Vickers
    Tom Baker Cancer Centre, Calgary, AB, Canada Flinders Medical Centre, Adelaide, Australia NCIC Clinical Trials Group, Kingston, ON, Canada The Queen Elizabeth Hospital, Woodville, Australia Ludwig Oncology Unit, Austin Hospital, Heidelberg, Australia University of Western Australia, Perth, Australia Cabrini Hospital, Malvern, Australia Royal North Shore Hospital, Sydney University, Sydney, Australia Royal Melbourne Hospital, Parkville, Australia St Joseph s Health Center, Toronto, ON, Canada Fraser Valley Cancer Center, Fraser Valley, BC, Canada Toronto East General Hospital, Toronto, ON, Canada Mt Sinai Hospital, Toronto, ON, Canada The Moncton Hospital, Moncton, NB, Canada ANZGOG, Camperdown, Australia Peter MacCallum Cancer Centre, Melbourne, Australia Department of Medical Oncology, University of Illinois at Chicago 60612
    J Clin Oncol 29:3601. 2011
    ..We explored this relationship in a prior clinical trial of CET plus BSC versus BSC in patients with pretreated ACC, in which magnesium (Mg) was prospectively collected at baseline and monthly...
  22. ncbi request reprint Safety and pharmacokinetics (PK) of motesanib diphosphate in combination with gemcitabine (G) and erlotinib (E) for the treatment of patients (pts) with solid tumors
    D Kotasek
    Adelaide Cancer Center, Ashford, Australia Austin Hospital, Austin Health, Heidelberg, Australia Princess Margaret Hospital, Toronto, ON, Canada Amgen Inc, Thousand Oaks, CA Queen Elizabeth Hospital, Adelaide, Australia
    J Clin Oncol 26:3560. 2008
    ..3560 Background: Motesanib diphosphate is an oral investigational, highly selective inhibitor of VEGF, PDGF and Kit receptors. In advanced cancer, inhibition of EGFR and VEGFR, with or without chemotherapy, has shown promising activity...
  23. ncbi request reprint Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study
    A J Weickhardt
    Ludwig Institute for Cancer Research, Heidelberg, Australia Austin Health, Heidelberg, Australia ANZGOG, Camperdown, Australia National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia NHMRC Clinical Trials Centre, Sydney, Australia The Queen Elizabeth Hospital, Woodville, Australia Ludwig Institute for Cancer Research, Melbourne, Australia Ludwig Oncology Unit, Austin Hospital, Heidelberg, Australia
    J Clin Oncol 29:3531. 2011
    ..We tested this hypothesis using tumor samples from patients in the MAX study...
  24. doi request reprint A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer
    M Michael
    Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Cancer Chemother Pharmacol 71:321-30. 2013
    ..This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities...
  25. doi request reprint 18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma
    A Azad
    Ludwig Institute Oncology Unit, University of Melbourne, Austin Hospital, Austin Health, Melbourne, Vic, Australia
    Med Oncol 27:230-2. 2010
    ....
  26. pmc Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity
    G Chong
    Austin Health, Heidelberg, Vic, Australia
    Ther Adv Med Oncol 2:309-17. 2010
    ..Further randomized data, particularly for patients with potentially resectable liver metastases, are required in order to fully define the role of bevacizumab in the increasingly complex management paradigm for this disease...